Massachusetts Financial Services Co. MA Has $23.16 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Massachusetts Financial Services Co. MA lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 0.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 175,777 shares of the company’s stock after selling 133 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.18% of Neurocrine Biosciences worth $23,160,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Headinvest LLC bought a new position in Neurocrine Biosciences in the third quarter valued at approximately $28,000. Lindbrook Capital LLC lifted its position in Neurocrine Biosciences by 85.0% in the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after acquiring an additional 96 shares in the last quarter. EdgeRock Capital LLC bought a new stake in Neurocrine Biosciences in the 4th quarter valued at $31,000. Benjamin F. Edwards & Company Inc. acquired a new position in Neurocrine Biosciences in the 4th quarter worth $33,000. Finally, Sunbelt Securities Inc. increased its holdings in Neurocrine Biosciences by 34.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock worth $37,000 after purchasing an additional 83 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on NBIX shares. Canaccord Genuity Group boosted their price target on Neurocrine Biosciences from $154.00 to $164.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. JPMorgan Chase & Co. upped their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. HC Wainwright raised their price target on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. The Goldman Sachs Group boosted their price objective on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Finally, Barclays raised their target price on shares of Neurocrine Biosciences from $150.00 to $169.00 and gave the company an “overweight” rating in a research report on Thursday, May 2nd. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $148.96.

Get Our Latest Analysis on Neurocrine Biosciences

Neurocrine Biosciences Stock Up 0.3 %

Neurocrine Biosciences stock opened at $142.29 on Friday. The company’s 50-day moving average price is $138.56 and its two-hundred day moving average price is $130.91. The stock has a market cap of $14.32 billion, a P/E ratio of 39.20 and a beta of 0.28. Neurocrine Biosciences, Inc. has a twelve month low of $89.04 and a twelve month high of $148.37.

Insider Activity

In related news, insider Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $145.06, for a total transaction of $725,300.00. Following the completion of the sale, the insider now directly owns 7,507 shares of the company’s stock, valued at approximately $1,088,965.42. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Richard F. Pops sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the transaction, the director now directly owns 29,512 shares of the company’s stock, valued at $3,909,454.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the completion of the sale, the insider now owns 7,507 shares of the company’s stock, valued at $1,088,965.42. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 194,664 shares of company stock valued at $26,877,417. 4.30% of the stock is owned by insiders.

About Neurocrine Biosciences

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Featured Stories

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.